News & Updates

Show Multimedia Only
Nelonemdaz safe but fails to improve outcomes in stroke Nelonemdaz safe but fails to improve outcomes in stroke

Nelonemdaz safe but fails to improve outcomes in stroke

01 Nov 2022

Treatment with nelonemdaz, a multitarget neuroprotectant that selectively blocks N-methyl-D-aspartate receptors and scavenges free radicals, does not appear to significantly improve stroke outcomes as compared with placebo, although nelonemdaz-treated patients show a greater tendency toward achieving modified Rankin Scale scores of 0–2 at 12 weeks, according to the results of a phase II study.

01 Nov 2022